The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global biosurgery market reached a value of US$ 12.2 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 18.2 Billion by 2027, exhibiting a CAGR of 6.95% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Biosurgery is a medical procedure that involves the use of natural, synthetic or semi-synthetic materials to seal surgical incisions and wounds. It is widely used for preventing excessive blood loss, providing adhesion for wound or tissue sealing and repairing damaged tissues and bones. Biosurgeries are usually conducted through various hemostatic, sealant, soft tissue repair, bone graft substitute, adhesion prevention and staple line reinforcement products. They also utilize natural allografts, cultured epithelial autografts and xenografts for minimizing intra and post-operative complications and promoting faster recovery of the patients. As a result, they are widely used for neurological, cardiovascular, orthopedic, spinal, thoracic and reconstruction surgeries.
The increasing prevalence of musculoskeletal disorders that require treatment through surgical procedures is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more prone to osteoporosis and other chronic medical ailments, is providing a thrust to the market growth. Patients and healthcare providers are widely adopting biosurgeries for effective blood loss management in patients through minimally invasive (MI) hemostatic agents and surgical sealants in place of traditionally used sutures and staples. In line with this, the rising incidents of sports-related injuries and accidental traumas is also contributing to the growth of the market. Additionally, various technological advancements, such as the development of plasma-based, multi-functional and multi-use products for biosurgeries, are favoring the growth of the market. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.
IMARC Group provides an analysis of the key trends in each sub-segment of the global biosurgery market report, along with forecasts for growth at the global and regional level from 2022-2027. Our report has categorized the market based on product, source, application and end user.
Breakup by Product:
Breakup by Source:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc.
|Base Year of the Analysis||2021|
|Segment Coverage||Product, Source, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||B. Braun Melsungen AG, Baxter International Inc., Becton Dickinson and Company, CryoLife Inc., CSL Limited, Hemostasis LLC, Integra Lifesciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Pfizer Inc., Sanofi S.A., Smith & Nephew plc, Stryker Corporation and Surgalign Spine Technologies Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at